WO2025107579 - COMPOUND TARGETING UBIQUITIN KRAS PROTEIN DEGRADATION AGENT, AND USE THEREOF
National phase entry:
Publication Number
WO/2025/107579
Publication Date
30.05.2025
International Application No.
PCT/CN2024/097697
International Filing Date
06.06.2024
Title **
[English]
COMPOUND TARGETING UBIQUITIN KRAS PROTEIN DEGRADATION AGENT, AND USE THEREOF
[French]
COMPOSÉ CIBLANT L'AGENT DE DÉGRADATION DE LA PROTÉINE KRAS DE L'UBIQUITINE ET SON UTILISATION
[Chinese]
一种靶向泛KRAS蛋白降解剂的化合物及其应用
Applicants **
BETTA PHARMACEUTICALS CO., LTD
Inventors
XU, Renqi
YANG, Xiaofeng
ZHANG, Hongbo
LU, Lu
WANG, Ze
ZHENG, Hang
HE, Jiangqi
LI, Tengfei
FANG, Longcheng
LIN, Yuanwang
LU, Yuan
WU, Hao
ZHOU, Quan
LAN, Hong
WANG, Jiabing
DING, Lieming
Priority Data
202311543432.2
20.11.2023
CN
202410097043.X
24.01.2024
CN
202410145511.6
02.02.2024
CN
202410621599.4
17.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2565 | |
| EPO | Filing, Examination, Granting | 19386 | |
| Japan | Filing, Examination, Granting | 2553 | |
| South Korea | Filing, Examination, Granting | 3099 | |
| USA | Filing, Examination, Granting | 6340 |
Total:
33,943
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A compound targeting a KRAS protein degradation agent, and a use thereof. The compound is a compound having an F-L-M structure, or a tautomer, racemate, enantiomer, or diastereomer thereof, or a mixture thereof or a pharmaceutically acceptable salt thereof, wherein F is a KRAS protein binding fragment, L is a linking unit for linking F and M, and M is a VHL binding fragment. The compound can be used for treating diseases caused by KRAS mutation or amplification.[French]
L'invention concerne un composé ciblant un agent de dégradation de protéine KRAS et son utilisation. L'invention concerne un composé qui est un composé ayant une structure F-L-M ou un tautomère, racémate, énantiomère ou diastéréomère de celui-ci ou un mélange de ceux-ci ou un sel pharmaceutiquement acceptable de celui-ci, F étant un fragment de liaison à la protéine KRAS ; L étant une unité de liaison pour lier F et M, et M étant un fragment de liaison VHL. Le composé peut être utilisé pour traiter des maladies provoquées par une mutation ou une amplification KRAS.[Chinese]
一种靶向KRAS蛋白降解剂的化合物及其应用。化合物为具有F-L-M结构的化合物，或其互变异构体、外消旋体、对映异构体、非对映异构体、或其混合物形式或其可药用的盐。F为KRAS蛋白结合片段，L为连接F和M的连接单元，M为VHL结合片段。化合物可用于治疗KRAS突变或扩增引起的疾病。